[go: up one dir, main page]

WO2015162504A1 - Nouveau dosage et nouvelles utilisations de l'ofatumumab - Google Patents

Nouveau dosage et nouvelles utilisations de l'ofatumumab Download PDF

Info

Publication number
WO2015162504A1
WO2015162504A1 PCT/IB2015/051473 IB2015051473W WO2015162504A1 WO 2015162504 A1 WO2015162504 A1 WO 2015162504A1 IB 2015051473 W IB2015051473 W IB 2015051473W WO 2015162504 A1 WO2015162504 A1 WO 2015162504A1
Authority
WO
WIPO (PCT)
Prior art keywords
ofatumumab
dose
week
suppressing amount
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/051473
Other languages
English (en)
Inventor
Daren J. AUSTIN
Philippa A. CHARLTON
Immanuel FREEDMAN
James H. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2015162504A1 publication Critical patent/WO2015162504A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Definitions

  • the present invention relates to a novel dosing regimen for ofatumumab to treat pemphigus diseases.
  • Pemphigus is a group of rare autoimmune diseases that cause blistering of the skin arid mucous membranes (mouth, nose, throat, eyes, and genitals). More specifically, pemphigus vulgaris (PV) is a chronic, debilitating, and potentially life-threatening autoimmune vesiculobullous disorder that is characterized by mucocutaneous blisters. Without treatment, such blistering eventually leads to erosions in the skin, resulting in significant morbidity and mortality.
  • PV pemphigus vulgaris
  • pemphigus There are several types of pemphigus and other similar autoimmune blistering disorders.
  • the type of disease depends on what layer in the skin the blisters form and where they are located on the body. Blisters always occur on or near the surface of the skin, which is called the epidermis. People with pemphigus vulgaris, for example, have blisters that occur within the lower layer of the epidermis, while people with pemphigus foiiaceus have blisters that form in the topmost layer.
  • the type of antibody that is attacking the skin typically defines the type of disease present.
  • Pemphigus vulgaris is the most common type of pemphigus in the United States and Europe. Soft and limp blisters appear on healthy -looking skin and mucous membranes. The sores almost alwa s start in the mouth. The blisters of pemphigus vulgaris form within the deep layer of the epidermis, and are often painful. Blistered skin becomes so fragile that it may peel off by rubbing a finger on it. The blisters normally heal without scarring, but pigmented spots (spots where skin appears darker than the surrounding skin) may remain for a number of months.
  • Pemphigus vegetans is a. form of pemphigus with thick sores in the groin and under the arms.
  • Pemphigus foliaceiis involves crusted sores or fragile blisters that often appear first on the face and scalp and later on the chest and other parts of the body. Unlike pemphigus vulgaris, blisters do not form in the mouth. The sores are superficial and often itchy, and are rarely as painful as pemphigus vulgaris blisters. There may also be loose, moist scales on the skin.
  • IgA pemphigus is a. blistering disorder in which a different type of antibody binds to the cell surface of epidermal ceils. This disease is different, from other forms of pemphigus because it involves a different type of antibody (called IgA) than other types. The disease may result in blisters similar to those seen in pemphigus foliaceiis, or it may involve many smal l bumps containing pus. This is the most, benign, or least harmful, form of pemphigus.
  • Paraneoplastic pemphigus is distinct from pemphigus, but shares some features of it. It occurs in people with certain types of cancer, including some lymphomas and leukemias. it often involves severe ulcers of the mouth and lips, cuts and scarring of the lining of the eye and eyelids, and skin blisters. Because the antibodies also target the membranes lining the airways, patients may develop life-threatening problems in the lungs. This disease is different from other types of pemphigus, and the antibodies in the blood are different. Special tests may be needed to identit paraneoplastic pemphigus.
  • Pemphigoid is also an autoimmune blistering disorder, characterized by splitting where the epidermis and the dermis (the layer below the epidermis) meet, causing deep, tense (taut or rigid) blisters that do not break easily.
  • Pemphigus causes a separation within the epidermis, and the blisters are soft, limp, and easily broken. This is because the antibodies attack cells where the epidermis and dermis (the layer below the epidermis) meet.
  • pemphigus and pemphigoid are treated with similar medications. Severe cases may require different treatment. Treatment for pemphigus in general and specifically pemphigus vulgaris involves using one or more drugs. High-dose oral corticosteroids, such as prednisone or prednisolone, are the main treatment for pemphigus. High doses are often required to bring pemphigus under control. To minimize the side effects, corticosteroid levels are reduced slowly to the lowest level required to prevent new blisters or sores from appearing. Many patients will go into complete remission with treatment, although this may take a number of years. Other patients will need to continue to take small doses of medication to keep the disease under control.
  • corticosteroids such as prednisone or prednisolone
  • Prednisone is usually taken by mouth, but can also be injected into a vein, muscle, or directly into a blister.
  • the route administered depends on the type and severity of disease. For pemphigoid, a corticosteroid cream will typically be used directly on the blisters.
  • immunosuppressive drugs are often added to a patient's treatment. These are drugs that stop or slow down the immune system's response to what it sees as an attack on the body. They include, but are not limited to the immunosuppresants: Mycophenolate (mofetil and sodium salts),
  • Azathioprine Cyclophosphamide, Methotrexate, and Cyclosporine.
  • Other drugs that may be used include, but are not limited to Diamino diphenyi sulfone (Dapsone), and other antibiotics such as tetracycline, and intravenous immunoglobulin.
  • immunosuppressive drugs to treat pemphigus can also increase the chances of developing an infection and may cause neutropenia (a decrease in the white blood cells in the blood) inflammation of the liver, nausea, vomiting, or allergic reactions.
  • People with severe pemphigus that cannot be control led with corticosteroids may undergo plasmapheresis, a treatment in which the blood containing the damaging antibodies is removed and replaced with blood that is free of antibodies.
  • plasmapheresis a treatment in which the blood containing the damaging antibodies is removed and replaced with blood that is free of antibodies.
  • Such patients can also be treated with IVIg (or IVIG), or intravenous im unoglobulin, which is given daily for 3 to 5 days, every 2 to 4 weeks for 1 to several months.
  • Plasmapheresis and IVIg are both very expensive treatments, and require large amounts of donated and specially processed blood.
  • Rituximab (Rituxan/MabTheraTM) is a chimeric monoclonal antibody (comprised of human and mouse components) that selectively depletes B cells bearing cluster of differentiation 20 (CD20 + B cells). Humanized or fully human monoclonal antibodies may have more favorable pharmacokinetics, better efficacy and lower immunogenicity than chimeric antibodies. Intravenous (IV) rituximab, has been reported to successfully treat PV in case-series reports in severe or refractory disease [Ahmed AR, et al., N Engl J Med. 2006;355: 1772- 1779; Cianchini et al., Arch Dermatol.
  • Ofatumumab is a fully human anti-CD20 monoclonal antibody. More specifically, ofatumumab is a novel human IgGlk lytic monoclonal antibody that specifically binds to the human CD20 antigen, which is expressed only in B lymphocytes from the pre-B-cell stage to the plasmacytoid immunoblast stage. This antibody has previously been studied by GlaxoSmithKline/Genmab in a placebo-controlled trial using an intravenous (IV) formulation (GEN414). It is approved as Arzerra®, as an intravenous injection, for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
  • CLL chronic lymphocytic leukemia
  • the present invention provides a method of treating, or arresting pemphigus in a patient suffering therefrom, comprising administering to the patient a novel dosing regimen of ofatumumab.
  • the pemphigus disease is pemphigus vulgaris.
  • One aspect of the invention is a method of treating, or arresting pemphigus in a patient suffering therefrom requiring administration of a dose suppressing amount of ofatumumab sufficient to suppress B cells between a dosing interval.
  • the dosing interval is every 4 weeks for up to a year.
  • the dose suppressing amount of ofatumumab sufficient to suppress B cells is a depleting or fully-depleting dosage amount.
  • the method of treating, or arresting Pemphigus in a patient suffering therefrom comprises administration to the patient a plurality of doses over a course of treatment time period.
  • the course of treatment time period includes dosing intervals.
  • a loading dose is given at week zero (day 1), and then a dosage is administered at each dosing interval thereafter.
  • a loading dose is given at week zero (day 1), and then at the next dosage interval an additional loading dose is also administered, followed subsequently with a lower dose at each dosing interval thereafter.
  • the dosing interval is a 4 week doing time period.
  • the course of treatment time period is up to 56 weeks.
  • Maintenance therapy may be the same dose suppressing amount administered at the same or at reduced dosing intervals.
  • Another aspect of the invention is a method of treating, or arresting a pemphigus disease in a patient suffering therefrom, comprising administering to said patient a dose depleting or dose suppresing amount of ofatumumab at week 1, followed by subsequent administration of a dose suppressing amount of ofatumumab at 4 week intervals, and wherein the dose suppressing amount of ofatumumab is sufficient to suppress B cells between dosing intervals.
  • Another aspect of the invention is ofatumumab for use in treating, or arresting a pemphigus disease in a patient suffering therefrom, comprising administering to said patient a dose suppressing amount of ofatumumab at week 1, followed by subsequent administration of a dose suppressing amount of ofatumumab at 4 week intervals, and wherein the dose suppressing amount of ofatumumab is sufficient to suppress B cells between dosing intervals.
  • Another aspect of the invention is a method for controlling the flare or relapse of a pemphigus disease in a patient suffering therefrom comprising administering to said patient a dose suppressing amount of ofatumumab at week 1, followed by subsequent administration dosing of a dose suppressing amount of ofatumumab at 4 week intervals, and wherein the dose suppressing amount of ofatumumab is sufficient to suppress B cells between dosing intervals.
  • Another aspect of the invention is ofatumumab for use in controlling the flare or relapse of a pemphigus disease in a patient suffering therefrom comprising administering to said patient a dose suppressing amount of ofatumumab at week 1, followed by subsequent administration dosing of a dose suppressing amount of ofatumumab at 4 week intervals, and wherein the dose suppressing amount of ofatumumab is sufficient to suppress B cells between dosing intervals.
  • Another aspect of the invention is a method of reducing steroid therapy in a patient with pemphigus disease, comprising administering to said patient a dose suppressing amount of ofatumumab at week 1, followed by subsequent administration dosing of a dose suppressing amount of ofatumumab at 4 week intervals, and wherein the dose suppressing amount of ofatumumab is sufficient to suppress B cells between dosing intervals.
  • Yet another aspect of the invention is ofatumumab for use in reducing steroid therapy in a patient with pemphigus disease, comprising administering to said patient a dose suppressing amount of ofatumumab at week 1, followed by subsequent dosing administration of a dose suppressing amount of ofatumumab at 4 week intervals, and wherein the dose suppressing amount of ofatumumab is sufficient to suppress B cells between dosing intervals
  • Another aspect of the invention is a method of reducing immunosuppressive therapy in a patient receiving an immunosuppressive therapeutic agent with pemphigus disease, comprising administering to said patient a dose suppressing amount of ofatumumab at week 1, followed by subsequent dosing administration of a dose suppressing amount of ofatumumab at 4 week intervals, and wherein the dose suppressing amount of ofatumumab is sufficient to suppress B cells between dosing intervals, and reducing the dose or eliminating the dose of the immunosuppressive therapeutic agent over the course of treatment.
  • Yet another aspect of the invention is ofatumumab for use in reducing immunosuppressive therapy in a patient receiving an immunosuppressive therapeutic agent with pemphigus disease, comprising administering to said patient a dose suppressing amount of
  • the present invention provides for a method of treating, or arresting Pemphigus in a patient suffering therefrom, comprising administering to the patient a novel dosing regimen of ofatumumab.
  • the Pemphigus disease is pemphigus vulgaris.
  • One aspect of the invention is a method of treating, or arresting Pemphigus in a patient suffering therefrom requires administration of a dose suppressing amount of ofatumumab sufficient to suppress B cells between a dosing interval.
  • the dosing interval is every 4 weeks for up to a year. In another embodiment the dosing interval is every 8 weeks, for up to a year.
  • the dose suppressing amount of ofatumumab sufficient to suppress B cells is a depleting or fully-depleting dosage amount.
  • Another embodiment of the present invention is the use of ofatumumab for treatment or arrestation of pemphigus in a patient suffering therefrom by administering to the patient an improved dosing regimen of ofatumumab wherein the dosing regimen is a dose
  • administration of ofatumumab for any of the uses herein is preferably by the subcutaneous (SC) route.
  • the method of treating, or arresting pemphigus in a patient suffering therefrom comprises administration to the patient a plurality of doses over a course of treatment time period.
  • a loading dose is given at week zero (day 1), and then a dosage is administered at each dosing interval thereafter.
  • a loading dose is given at week zero (day 1), and then at the next dosage interval an additional loading dose is also administered, followed subsequently with a lower dose at each dosing interval thereafter.
  • a first dose of 20 mg is given with an additional dose of 20mg to equal a loading dose of 40mg; at the second dosing interval at 4 weeks, a second dose of 20mg is also given with another 20mg (e.g., a second loading dose) to equal 40mg administered, subsequently at the remaining dosing intervals of 4 weeks time,
  • administration of 20mg is given, e.g. at 8 weeks, 12 weeks, 16 weeks etc. out to either 48 weeks or a full year of treatment, e.g. 56 weeks.
  • ofatumumab is administered subcutaneously at week zero (day 1) followed by a dosing interval of every 4 weeks.
  • the first dose of 20 mg is given with an additional loading dose to equal 40mg, and then subsequent doses of 20mg are administered over the course of 4 week intervals, such as at 4 weeks, 8 weeks, 12 weeks, etc. out to either 48 weeks or a full year of treatment, e.g. 56 weeks.
  • Another aspect of the invention is a method of controlling the flare or relapse of pemphigus in a patient suffering therefrom comprising administering to the patient at least one dose suppressing and/or fully-depleting dose of ofatumumab.
  • One aspect of controlling the flare or relapse of Pemphigus in a patient suffering therefrom requires the administration of a dose suppressing amount of ofatumumab sufficient to suppress B cells between the dosing intervals.
  • the dosing interval is every 4 weeks for up to a year.
  • the dosing interval is every 8 weeks, for up to a year.
  • the dose suppressing amount of ofatumumab sufficient to suppress B cells for this method is a depleting or fully-depleting dosage.
  • the dose suppressing amount of ofatumumab is 20mg, 30mg, 40mg or 60mg.
  • the method of controlling the flare or relapse of pemphigus will be a similar treatment as indicated above with a 40mg loading dose, followed by either a 20mg or 40mg second dose at 4 weeks, and then a 20mg dose every 4 weeks thereafter for up to 1 year of treatment.
  • the pemphigus disease is pemphigus vulgaris.
  • One embodiment of the present invention is the use of ofatumumab for controlling the flare or relapse of Pemphigus in a patient suffering therefrom by administering to the patient an improved dosing regimen of ofatumumab wherein the dosing regimen is a dose suppressing amount of ofatumumab sufficient to suppress B cells between dosing intervals, and the dosing interval is every 4 weeks for up to a year.
  • a method for treating pemphigus in a patient suffering therefrom while concomitantly reducing the use of steroids comprising administering to the patient a plurality of doses over a course of treatment time period.
  • the patient is requiring use of more than 20mg of steroid or 1.5mg/kg of steroid usage (which ever is higher) for disease control prior to administration of ofatumumab.
  • the steroid is oral prednisone.
  • a method for treating pemphigus in a patient suffering therefrom while concomitantly reducing the use of steroids during said treatment will also require administration of a dose suppressing amount of ofatumumab sufficient to suppress B cells between the dosing intervals.
  • the dose of ofatumumab is 20mg, 30mg, 40mg or 60mg.
  • the pemphigus disease is pemphigus vulgaris.
  • One embodiment of the present invention is the use of ofatumumab for treating Pemphigus in a patient while concomitantly reducing the use of steroids in said patient by administering to the patient an improved dosing regimen of ofatumumab wherein the dosing regimen is a dose depleting and/or dose suppressing amount of ofatumumab sufficient to suppress B cells between dosing intervals, and the dosing interval is every 4 weeks for up to a year.
  • Another aspect of this invention is a method of reducing immunosuppressive therapy in a patient with Pemphigus disease, comprising administering to said patient will be a similar treatment as indicated above with a 40mg loading dose, followed by either a 20mg or 40mg second dose at 4 weeks, and then a 20mg dose every 4 weeks thereafter for up to 1 year of treatment, and reducing the dose or eliminating the dose of the immunosuppressive therapeutic agent over the course of treatment.
  • the method of reducing immunosuppressive therapy in a patient with pemphigus disease will also require the administration of a dose depleting or dose suppressing amount of ofatumumab sufficient to suppress B cells between the dosing intervals.
  • the dose suppressing amount of ofatumumab is an amount sufficient to be a depleting or fully depleting dose.
  • the dose of ofatumumab is 20mg, 30mg, 40mg or 60mg.
  • a method of reducing immunosuppressive therapy in a patient with Pemphigus disease there will be a similar treatment as indicated above with a 40mg loading dose, followed by either a 20mg or 40mg second dose at 4 weeks, and then a 20mg dose every 4 weeks thereafter for up to 1 year of treatment.
  • the Pemphigus disease is pemphigus vulgaris.
  • One embodiment of the present invention is the use of ofatumumab for reducing immunosuppressive therapy in a patient with Pemphigus disease by administering to the patient an improved dosing regimen of ofatumumab wherein the dosing regimen is a dose suppressing amount of ofatumumab sufficient to suppress B cells between dosing intervals, and the dosing interval is every 4 weeks for up to a year.
  • the loading dose followed at 4 week intervals may end after a 5 cycle treatment, e.g. at week 16.
  • the treatment may end after a 6 cycle administration of drug, e.g. week 20.
  • the treatment may end after a 7 cycle administration, e.g. week 24, etc.
  • the 4 week dosing interval may be extended to dosing every 2 cycles, e.g. at 8 week intervals or even 3 cycles intervals, e.g. every 12 weeks with the dose of ofatumumab being administered as 20mg, 30mg, 40mg or 60mg.
  • the invention provides for an anti-CD20 antibody, preferably ofatumumab or rituximab, for use in the treatment or arrest of pemphigus in a patient suffering therefrom, wherein the antibody is administered at a dose suppressing amount sufficient to suppress B cells between a dosing interval.
  • the invention provides an anti-CD20 antibody, suitably ofatumumab or rituximab, for use in the treatment of pemphigus by prevention of flare or relapse in a patient suffering therefrom, wherein the antibody is administered at a dose suppressing amount sufficient to suppress B cells between a dosing interval.
  • the anti-CD20 antibody is ofatumumab.
  • the course of treatment time period includes dosing intervals.
  • a loading dose is given at week zero (day 1), and then a dosage is administered at each dosing interval thereafter.
  • a loading dose is given at week zero (day 1), and then at the next dosage interval an additional loading dose is also administered, followed subsequently with a lower dose at each dosing interval thereafter.
  • the dosing interval is a 4 week doing time period.
  • the course of treatment time period is up to 56 weeks. Maintenance therapy may be the same dose suppressing amount administered at the same or at reduced dosing intervals.
  • Pemphigus vulgaris is an acquired, rare, chronic, debilitating, and potentially life- threatening autoimmune vesiculobullous disorder, characterized by mucocutaneous erosions or blisters.
  • the disease is caused by pathogenic antibodies directed against desmoglein 1 and 3, which are members of the desmosomal cadherin family.
  • desmoglein 1 and 3 which are members of the desmosomal cadherin family.
  • the in vivo binding of these anti-desmoglein autoantibodies mainly IgG4 and IgGl
  • These blisters eventually lead to erosions in the skin which, prior to steroid therapy, resulted in significant mortality.
  • pemphigus represents a group of rare autoimmune blistering diseases caused by anti-desmoglein antibodies (including pemphigus vulgaris (PV), pemphigus folicaeus, and paraneoplastic pemphigus), of which pemphigus vulgaris is the most common.
  • Pemphigus vulgaris presents with peak frequency generally occurring at 30 to 60 years of age and older, with an incidence of approximately 5-6 per million worldwide and a mortality rate of ⁇ 10%.
  • the disease caused by pathogenic antibodies directed against desmoglein (Dsg) 1 and 3, are members of the desmosomal cadherin family.
  • Dsg desmoglein
  • the in vivo binding of these anti-Dsg autoantibodies mainly IgG4 and IgGl
  • causes a loss of adhesion between keratinocytes, and the resultant formation of intra-epidermal blisters [Amagai M, et al. J Invest Dermatol. 1995 Aug; 105(2):243-7].
  • the PV Dsg3-/-mouse model demonstrated telogen hair loss, providing the first cutaneous manifestation of Dsg3 dysfunction in adult mice [Koch et al., J Cell Sci 1998, 111 :2529- 2537]. These findings also suggested that anti-Dsg3 autoantibodies directly interfered with the adhesive function of Dsg3 to cause blisters.
  • Another PV mouse model has been developed by the adoptive transfer of splenocytes from recombinant Dsg3 -immunized Dsg3-/- mice to Rag2-/-immunodeficient mice that expressed Dsg3.
  • a deposition of IgG on keratinocyte cell surfaces in stratified squamous epithelia is noted in this PV mouse model as well as circulating anti-Dsg3 IgG antibodies [Ohyama M, et al., J Invest
  • B-cell depletion has been documented with IV administration of ofatumumab in subjects with rheumatoid arthritis and multiple sclerosis, and with subcutaneous (SC) administration of ofatumumab in subjects with rheumatoid arthritis (Study OF Al l 0867).
  • a "dose depleting" or “dose suppressing amount” of ofatumumab is that which is expected to suppress B-cells to below the limit of quantification (LLQ). While it is possible to have “depletion to 0 cells/ul” occurring, a surrogate endpoint, such as suppression to 32 cells/ul is within the range of clinical effect. Thus a “dose suppressing" amount is a clinical effect of 32cells/ul and a “depleting” or “fully depleting dose” would be to the limit of quantification, such as -5-7 cells/ul.
  • Both terminologies, e.g. dose suppressing and dose depleting are used interchangeably herein within the context of this invention as are the terminologies, e.g. depleting and fully depleting.
  • systemic corticosteroids are currently the most commonly utilized therapy for the management of pemphigus vulgaris, multiple side-effects associated with high-dose corticosteroids are seen. This can increase morbidity and may necessitate the use of other adjuvant steroid-sparing therapies.
  • Week one may refer to, the 8 th day of treatment (wherein the initial dose is administered to the patient on day 1 of treatment), "week 4" as used herein may refer to the 29 th day of treatment, e.g. administration of ofatumumab, "week 12" as used herein may refer to the 85 th day of treatment, e.g. administration of ofatumumab, etc. It will be understood that the exact timing of the administration - i.e. the exact day of delivery - may not be critical.
  • delivery may be within +/-7 days of the stated day, +/-5days of the stated day, +/- 3 days of the stated day, +/-2days of the stated days or +/- lday of the stated day.
  • delivery could be on day 1, day 8 (+/- 3 days), day 85 (+/- 3 days).
  • the method may also comprise the administration to the patient of a tolerizing dose, wherein the tolerizing dose is administered to the patient prior to the delivery of the at least one sub-depleting dose.
  • the tolerizing dose may be administered about 1 week prior to the delivery of the (first) at least one sub- depleting dose.
  • the tolerizing dose is between about 0.3mg and 3mg of ofatumumab. In another embodiment, the tolerizing dose is about 3mg of ofatumumab.
  • B cells during the inter-dosing intervals of ofatumumab administration.
  • B cell suppression is improved. Achieving adequate B cell depletion is believed to be essential for maintenance of efficacy in pemphigus treatment although no threshold for B cell depletion has been demonstrated. It is believed that dividing the dose of drug to administer 20mg every 4 weeks, rather than 60mg every 12 weeks will achieve this goal. By administration of the higher loading dose and the subsequent additional higher dosage at week 4 a more rapid depletion of B-cells is believed to occur. It is expected to maintain a desired level of suppression during the inter-dosing intervals and which can be achieved with a non-loading dose of ofatumumab, such as 20mg, administrated approximately every 4 weeks.
  • additional loading doses such as 20mg of ofatumumab may be administered at the first dose, at the second dose (week 4) and even at the third dose (week 8) or longer if believed necessary. This would be followed thereafter by 20mg throughout the remaining 4 week cycles of treatment.
  • additional loading doses of ofatumumab such as 20mg may be administered at any of the dosing intervals, e.g. as presently indicated for the first dose, and the second dose (week 4) but also at the third dose (week 8) or the forth dose (week 12) or longer if believed necessary. This would be followed thereafter by 20mg throughout the remaining 4 week cycles of treatment.
  • the present invention relates to a method for treating pemphigus in a human patient comprising administering ofatumumab at an:
  • initial 20 mg dose followed with a second 20mg dose (e.g. a 40mg loading dose) administered at week one; followed by a 20 mg dose at week 4; and then every 8 weeks a dose of 20 mg for a multiple of cycles out to 56 weeks, e.g. weeks 12, 20, 28, 36, 44, and 52 weeks; or
  • initial 20 mg dose followed with a second 20mg dose (e.g. a 40mg loading dose) administered at week one; a 20mg dose followed with a second 20mg dose (e.g. a second 40mg loading dose) at week 4; and then every 8 weeks a dose of 20 mg for a multiple of cycles out to 56 weeks, e.g. weeks 12, 20, 28, 36, 44, and 52 weeks; or
  • initial 20 mg dose followed with a second 20mg dose (e.g. a 40mg loading dose) administered at week one; a 20mg dose followed with a second 20mg dose (e.g. a second 40mg loading dose) at week 4; and then every 4 weeks a dose of 30mg for a multiple of cycles out to 56 weeks, e.g. weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and 56 weeks.; or
  • the regimen may in fact be less than the full 48 -56 weeks of dosing.
  • Time to remission or sustained remission may be present after less than 10 doses, or less than 9 doses, or less than 8 doses, or less than 7 doses.
  • time to remission or sustained remission may be present after less than 6 doses.
  • time to remission or sustained remission may be present after less than 6 doses.
  • time to remission or sustained remission may be present after less than 4 doses.
  • maintenance therapy may be initiated at a lower dose than the one used in the regimen, or it may be administered at more infrequent scheduling.
  • the following definitions shall mean: Did not flare/relapse Achieved remission on minimal steroid therapy and did not subsequently have a flare/relapse of disease by Week 60
  • Time to remission off Time from randomization to the time the subject initially steroid therapy tapered off all steroids for >8 weeks with an absence of new or nonhealing (established) lesions by Week 60
  • Ofatumumab may be administered via any suitable route, such as nasal, inhalable, intrabronchial, intraalveolar, topical (including buccal, transdermal and sublingual), rectal, vaginal and/or parenteral route.
  • a pharmaceutical route such as nasal, inhalable, intrabronchial, intraalveolar, topical (including buccal, transdermal and sublingual), rectal, vaginal and/or parenteral route.
  • a pharmaceuticals such as nasal, inhalable, intrabronchial, intraalveolar, topical (including buccal, transdermal and sublingual), rectal, vaginal and/or parenteral route.
  • composition of the present invention is administered subcutaneously (SC), optionally intramuscularly, typically by injection.
  • SC subcutaneously
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
  • the term, "pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration or subcutaneous administration to human beings.
  • compositions for these administrations are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic, such as lignocaine, to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder, or water-free concentrate, in a hermetically sealed container, such as an ampoule or sachette, indicating the quantity of active agent.
  • composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and include epidermal, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendinous, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracranial, intrathoracic, epidural and intrasternal injection and infusion.
  • ofatumumab can be formulated according to the disclosure of
  • ofatumumab may be formulated as described in WO2012/096924. In another embodiment, ofatumumab may be formulated as the commercially available product, Azerra®, which although formulated for intravenous injection may be used subcutaneously.
  • ofatumumab is presently available as a parenteral injection to be prepared for administration as a 300mg or a 2000mg dose.
  • the label indicates that for a 300mg dose 3 single use vials of lOOmg are diluted with 0.9% sodium Chloride Injection, USP.
  • 2 single use lOOOmg vials are diluted with 50ml of 0.9% sodium Chloride Injection, USP.
  • the IV vials include as inactive ingredients include: lOmg/mL arginine, diluted hydrochloric acid, 0.019mg/mL edetate disodium, 0.2 mg/mL polysorbate 80, 6.8 mg/mL sodium acetate, 2.8 mg/mL sodium chloride, and Water for Injection, USP.
  • the vials contain no preservatives.
  • the commercial product may be used and diluted accordingly from a lOOmg/vial to deliver a 20mg, 30 mg, 40mg or 60mg dose.
  • prefilled syringes may be used having the appropriate concentration and dosage may be used for SC administration.
  • Ofatumumab is supplied as a liquid concentrate in 3-mL glass vials containing 1 mL of concentration 100 mg/mL drug product, or in 1-mL prefilled glass syringes with stake needles containing 0.6 mL of concentration 100 mg/mL drug product.
  • the contents of prefilled (0.6 mL) syringes of ofatumumab 60-mg syringe can be injected into a sterile vial and 0.4 mL of the resulting solution will be drawn into a new syringe to achieve a 20-mg ofatumumab (concentration 50 mg/mL) dose.
  • Ofatumumab may also be supplied in prefilled glass syringes containing 0.4 mL (20 mg) of concentration 50 mg/mL drug product.
  • compositions of the present invention include any and all suitable solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonicity agents, antioxidants and absorption delaying agents, and the like that are physiologically compatible with a compound of the present invention.
  • Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the present invention is contemplated.
  • Proper fluidity may be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions containing ofatumumab may also comprise pharmaceutically acceptable antioxidants for instance (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabi sulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid
  • compositions containing ofatumumab may also comprise isotonicity agents, such as sugars, polyalcohols such as mannitol, sorbitol, glycerol or sodium chloride in the compositions.
  • Pharmaceutically acceptable diluents include saline and aqueous buffer solutions.
  • compositions containing ofatumumab may also contain one or more adjuvants appropriate for the chosen route of administration, such as preservatives, wetting agents, emulsifying agents, dispersing agents, preservatives or buffers, which may enhance the shelf life or effectiveness of the pharmaceutical composition.
  • adjuvants appropriate for the chosen route of administration, such as preservatives, wetting agents, emulsifying agents, dispersing agents, preservatives or buffers, which may enhance the shelf life or effectiveness of the pharmaceutical composition.
  • An anti- CD20 antibody the present invention may for instance be admixed with lactose, sucrose, powders (e.g., starch powder), cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, and/or polyvinyl alcohol.
  • dihydrochloride thymocartin, Tio-TEPA, monophosphoryl-lipid A/microbacteria compositions, alum, incomplete Freund's adjuvant, montanide ISA, ribi adjuvant system, TiterMax adjuvant, syntex adjuvant formulations, immune-stimulating complexes (ISCOMs), gerbu adjuvant, CpG oligodeoxynucleotides, lipopolysaccharide, and polyinosinic:polycytidylic acid.
  • ofatumumab may be coated in a material to protect the antibody from the action of acids and other natural conditions that may inactivate the compound.
  • ofatumumab may be administered to a subject in an appropriate carrier, for example, liposomes, or a diluent.
  • Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al., J. Neuroimmunol. 7, 27 (1984)).
  • Pharmaceutically acceptable carriers for parenteral administration include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical
  • compositions of the present invention is contemplated.
  • Supplementary active compounds may also be incorporated into the compositions.
  • compositions for injection must typically be sterile and stable under the conditions of manufacture and storage.
  • the composition may be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.
  • the carrier may be a aqueous or nonaqueous solvent or dispersion medium containing for instance water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • the proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • isotonic agents for example, sugars, polyalcohols, such as glycerol, mannitol, sorbitol, or sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
  • Sterile injectable solutions may be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients e.g. as enumerated above, as required, followed by sterilization microfiltration.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients e.g. from those enumerated above.
  • sterile powders for the preparation of sterile injectable solutions examples of methods of preparation are vacuum drying and freeze- drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Sterile injectable solutions may be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by sterilization microfiltration.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • sterile powders for the preparation of sterile injectable solutions, examples of methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the method according to the invention may also comprise the step of administering additional pharmaceutically active agents with Ofatumumab.
  • Suitable additional pharmaceutically active agents include, but are not limited to, firategrast, fingolimod, natalizumab, methotrexate, interferon-gamma, cyclophosphamide, cyclosporine, corticosteroids such as prednisone and prednisolone, non-steroidal anti-inflammatory drugs (NSAIDs), such as paracetamol, and anti-histamines, such as ceterazine, or diphenhydramine.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • anti-histamines such as ceterazine, or diphenhydramine.
  • the invention provides a method of treating, or arresting pemphigus in a patient suffering therefrom, comprising administering to the patient an anti-CD 20 antibody, preferably ofatumumab, and one or more of a second pharmaceutical active agent.
  • the second pharmaceutical active agent is firategrast, fingolimod or natalizumab.
  • patients treated with the dosage regimen of the present invention may be a steroid niave patient who does not receive treatment with corticosteroids, or they may be patients who wish to reduce or limit their concurrent usage of steroids with a dosage regimen of the present invention.
  • Subcutaneously administering Ofatumumab in patients with Pemphigus will, based on disease remission, determine the efficacy of ofatumumab administered SC at a dose of 40 mg administered at week 1, a 40mg dose administered at week 4, and then a 20mg dose administered every 4 weeks for up to 56 weeks. Patients will be evaluated to determine disease flare and/or relapse during treatment with ofatumumab SC. Patients will be evaluated to see if there are reductions in co- administered steroids while maintaining disease control.
  • Study OPV116910 is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of ofatumumab SC in subjects with active PV, who have failed a previous attempt to taper steroid dosing
  • the study includes a Screening Period, a 48-week Treatment Period, and a 12-week Follow-up Period. Subjects will visit the clinic during Screening; at Baseline (Week 0); at Weeks 2, 4, 6, and 8; and then every 4 weeks from Week 8 through Week 60. Subjects will also have structured phone visits between each of the clinic visits from Week 10 through Week 22. It is anticipated that total duration of participation in this study will be approximately 72 weeks.
  • a Screening Period of 2 to 12 weeks will occur prior to randomization to allow subjects to achieve disease control (no new lesions for >2 weeks) using a stable oral dose of prednisone/prednisolone (20 mg/day up to 120 mg/day or 1.5 mg/kg/day [whichever is higher] for >2 weeks). Multiple visits to the clinic are permitted during this Screening Period to assess disease status and to adjust the oral prednisone/prednisolone dose. Once disease control is achieved, subjects who continue to satisfy the eligibility criteria may be randomized.
  • a Screening Period of up to 12 weeks will allow subjects who have active lesions at the initial Screening Visit to achieve disease control using a stable dose of 20 mg/day up to 120 mg/day (or 1.5 mg/kg/day, whichever is higher) of oral prednisone/prednisolone for >2 weeks.
  • subjects may be randomized to treatment, provided they continue to fully satisfy the eligibility criteria.
  • Subjects are co-administered acetaminophen/paracetamol and an antihistamine (such as cetirizine or an equivalent).
  • Subjects will remain on the stable daily oral steroid dose achieved during the Screening Period until Week 2, when they will begin steroid tapering; with the goal of reducing or eliminating the daily use of steroids, subjects will have their oral steroid dose reduced by 1 dose level every 2 weeks (as illustrated in Table 1 below). Subjects will remain on the standardized steroid taper schedule until the onset of disease flare/relapse (appearance of >3 new lesions within 1 month that do not heal spontaneously within 1 week, or when there is an extension of lesions that were present at the randomization visit). If a subject experiences disease flare/relapse, the prednisone/prednisolone dose will be increased by
  • the design of this study takes into account the low incidence and chronic relapsing nature of PV, and the fact that therapy with corticosteroids— albeit associated with significant side effects— represents the standard of care for management of PV.
  • the study is designed to evaluate the efficacy of ofatumumab SC in an environment where a subject requiring corticosteroids is undergoing a taper to minimal treatment or, ideally, no treatment with systemic steroids. For this reason, the study has been designed with 1 study group receiving ofatumumab SC and the other group receiving placebo, over a background of tapering steroids for both treatment arms. The dosing duration of 1 year will allow adequate time to assess time to remission in both study groups.
  • Historical data indicate that remission can be expected in approximately 54% of subjects in the placebo group (with steroid dose adjustment), and in about 80% of subjects in the ofatumumab SC group.
  • ofatumumab When administered via IV infusion, ofatumumab has been associated with infusion reactions that have occasionally led to temporary interruption or withdrawal of treatment.
  • premedication with acetaminophen/paracetamol, oral or IV antihistamine, and oral and/or IV glucocorticoids has been used in clinical studies involving oncology and rheumatoid arthritis populations.
  • oral doses of acetaminophen/paracetamol and antihistamine will be administered as premedication, 1 to
  • Two co-primary efficacy endpoints include but are not limited to the evaluation of:
  • SR Time to sustained remission (SR) on minimal steroid therapy (defined as time from randomization to the time the subject initially tapered his/her oral
  • prednisone/prednisolone dose to ⁇ 10 mg/day and maintained ⁇ 10 mg/day of oral prednisone/prednisolone with no new or nonhealing lesions for >8 weeks AND maintained that status until Week 60).
  • ⁇ Duration of remission on minimal steroid therapy (defined as total time of all periods during the 60 week period, from when the subject initially tapered his/her oral prednisone/prednisolone dose to ⁇ 10 mg/day and had remission, until initial flare/relapse or Week 60, whichever comes first).
  • Secondary Efficacy Endpoints include, but are not limited to:
  • Proportion of subjects achieving remission on minimal steroid therapy defined as subjects who had an absence of new or nonhealing lesions while on a
  • prednisone/prednisolone dose of ⁇ 10 mg/day for >8 weeks) at Week 60.
  • prednisone/prednisolone dose to ⁇ 10 mg/day and maintained ⁇ 10 mg/day of oral prednisone/prednisolone with no new or nonhealing lesions for >8 weeks) by Week 60.
  • Time to initial flare/relapse (defined as the time from randomization to the time that >3 new lesions within 1 month appear and do not heal spontaneously within 1 week, or to the time when there is an extension of lesions that were present at the randomization visit) by Week 60.
  • a flare/relapse is defined as new lesions that do not heal spontaneously within 1 week, or when there is an extension of lesions that were present at the randomization visit.
  • Prednisone/prednisolone is reduced by 1 dose level every 2 weeks, with the goal being elimination of prednisone/prednisolone.
  • taper dose by 20 mg every 2 weeks until the dose is 160 mg, at which point the decrements shown on the table above should be used.
  • prednisone/prednisolone will be increased by a rate of 1 to 4 levels per week until disease control is re-established.
  • the oral prednisone/prednisolone taper will then be reinitiated after disease control is maintained for 2 weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau schéma posologique pour l'ofatumumab pour traiter les maladies de type pemphigus .
PCT/IB2015/051473 2014-04-23 2015-02-27 Nouveau dosage et nouvelles utilisations de l'ofatumumab Ceased WO2015162504A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461982929P 2014-04-23 2014-04-23
US61/982,929 2014-04-23

Publications (1)

Publication Number Publication Date
WO2015162504A1 true WO2015162504A1 (fr) 2015-10-29

Family

ID=52693004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/051473 Ceased WO2015162504A1 (fr) 2014-04-23 2015-02-27 Nouveau dosage et nouvelles utilisations de l'ofatumumab

Country Status (1)

Country Link
WO (1) WO2015162504A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114375306A (zh) * 2019-09-11 2022-04-19 诺华股份有限公司 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
US12338290B2 (en) 2016-08-15 2025-06-24 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009407A1 (fr) 2007-07-06 2009-01-15 Smithkline Beecham Corporation Formulations d'anticorps
WO2011091138A1 (fr) * 2010-01-20 2011-07-28 Bayhill Therapeutics, Inc. Thérapie d'association pour traiter des maladies auto-immunes
WO2012096924A1 (fr) 2011-01-10 2012-07-19 Glaxo Group Limited Nouvelles utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009407A1 (fr) 2007-07-06 2009-01-15 Smithkline Beecham Corporation Formulations d'anticorps
WO2011091138A1 (fr) * 2010-01-20 2011-07-28 Bayhill Therapeutics, Inc. Thérapie d'association pour traiter des maladies auto-immunes
WO2012096924A1 (fr) 2011-01-10 2012-07-19 Glaxo Group Limited Nouvelles utilisations

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
AHMED AR ET AL., N ENGL J MED., vol. 355, 2006, pages 1772 - 1779
AMAGAI M ET AL., J INVEST DERMATOL., vol. 105, no. 2, August 1995 (1995-08-01), pages 243 - 7
ANONYMOUS: "EFFICACY AND SAFETY OF OFATUMUMAB IN TREATMENT OF PEMPHIGUS VULGARIS", 1 August 2013 (2013-08-01), XP002738545, Retrieved from the Internet <URL:http://www.trialdetails.com/detail/NCT01920477/Efficacy-and-Safety-of-Ofatumumab-in-Treatment-of-Pemphigus-Vulgaris> [retrieved on 20150416] *
ANONYMOUS: "Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder.", 4 July 2013 (2013-07-04), XP055183692, Retrieved from the Internet <URL:http://ir.genmab.com/common/download/download.cfm?companyid=AMDA-KPIBN&fileid=674178&filekey=1224f222-f753-4af3-ad74-865ea79113b7&filename=775300.pdf> [retrieved on 20150416] *
CIANCHINI ET AL., ARCH DERMATOL., vol. 143, no. 8, 2007, pages 1033 - 1038
CRAYTHOME ET AL., J AM ACAD DERMATOL., vol. 65, no. 5, 2011, pages 1064 - 1065
EMING ET AL., J INVEST DERMATOL., vol. 128, no. 1, 2008, pages 2850 - 2858
EMING ET AL., JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 128, 2008, pages 2850 - 2858
JOLY ET AL., N ENGL J MED., vol. 357, no. 6, 2007, pages 545 - 552
KASPERKIEWICS ET AL., BR J DERMATOL., vol. 166, 2012, pages 154 - 160
KEVIN GROGAN: "GSK tests ofatumumab in rare skin disorder", 4 July 2013 (2013-07-04), XP002738546, Retrieved from the Internet <URL:www.pharmatimes.com/article/13-07-04/GSK_tests_ofatumumab_in_rare_skin_disorder.aspx> [retrieved on 20150416] *
KIM ET AL., BR J DERMATOL., vol. 165, no. 3, 2011, pages 646 - 651
KOCH ET AL., J CELL SCI, vol. 111, 1998, pages 2529 - 2537
LESHEM ET AL., J AM ACAD DERMATOL., vol. 68, 2013, pages 404 - 411
LINDA K MARTIN ET AL: "A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 64, no. 5, 28 February 2011 (2011-02-28), pages 903 - 908, XP028190730, ISSN: 0190-9622, [retrieved on 20100507], DOI: 10.1016/J.JAAD.2010.04.039 *
LUNARDON ET AL., ARCH DERMATOL., vol. 148, no. 9, 2012, pages 1031 - 1036
MARTIN LK ET AL., J AM ACAD DERMATOL., vol. 64, no. 5, 2011, pages 903 - 908
MOUQUET ET AL., J INVEST DERMATOL., vol. 128, no. 12, 2008, pages 2859 - 2869
MOUQUET H ET AL., JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 128, 2008, pages 2859 - 2869
OHYAMA M ET AL., J INVEST DERMATOL., vol. 118, 2002, pages 199 - 204
ROBINSON JC ET AL., ORAL SURG ORAL MED ORAL PATHOL ORAL RADIOL ENDOD., vol. 84, no. 4, 1997, pages 349 - 355
STREJAN ET AL., J. NEUROIMMUNOL., vol. 7, 1984, pages 27

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12338290B2 (en) 2016-08-15 2025-06-24 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
CN114375306A (zh) * 2019-09-11 2022-04-19 诺华股份有限公司 奥法木单抗治疗患者中除多发性硬化症以外病症的管理

Similar Documents

Publication Publication Date Title
US20230348615A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
US20230277660A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
AU2017278245B2 (en) Composition and method for reducing neutropenia
US20230250174A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone
US20230330224A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
US20230295333A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
JPWO2020249693A5 (fr)
MXPA01010138A (es) Docetaxel en combinacion con rhumas her2 para el tratamiento de canceres.
US20170119752A1 (en) Nicotinic attenuation of cns inflammation and autoimmunity
US12053474B2 (en) Dosing regimens associated with extended release paliperidone injectable formulations
JP7370357B2 (ja) 医薬組成物
US8906357B2 (en) Treatment of multiple sclerosis with masitinib
WO2015162504A1 (fr) Nouveau dosage et nouvelles utilisations de l&#39;ofatumumab
JP7221956B2 (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
EP4137136A1 (fr) Schémas posologiques associés à des formulations injectables de palipéridone à libération prolongée
WO2008033041A1 (fr) Traitement contre le cancer
Rommer et al. Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions
J Marriott et al. Emerging therapies in relapsing-remitting multiple sclerosis
US20230270743A1 (en) Use of btk inhibitors in the treatment of diseases
US20240207199A1 (en) Fluorocarbon compositions and methods for enhancing immunotherapy
JP2024531314A (ja) 小児ｍｓを治療するためのオファツムマブ
KR100681626B1 (ko) 과다 반응성 염증 질환 및 자가면역질환의 치료를 위한 15-디옥시스페르구알린의 용도
Babiak Rituximab Biosimilar for Rheumatoid rthritis
WO2025209478A1 (fr) Méthodes de traitement de l&#39;anémie hémolytique auto-immune à anticorps chauds faisant appel au sovléplénib
htS Reserved New Molecular Entities

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15710920

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15710920

Country of ref document: EP

Kind code of ref document: A1